TORONTO, Aug. 05, 2026 (GLOBE NEWSWIRE) — Stack Capital Group Inc., (“Stack Capital” or the “Company”) (TSX:STCK) today announced its financial results for the period ended June 30, 2026. Stack Capital reports all amounts in Canadian Dollars unless otherwise stated. FINANCIAL SUMMARYBook Value per Share (BVpS): $20.25, compared to $16.57 as at March 31, 2026 (+22% increase) Total Book Value: $313 millionThe quarter reflected meaningful value creation across the portfolio, led by SpaceX, Fluidstack, CoreWeave and X-Energy. PORTFOLIO COMPANY HIGHLIGHTS SpaceXSpaceX completed its record-setting initial public offering and began trading on Nasdaq under the ticker SPCX. The offering was priced at US$135 per share, raising US$75 billion at an approximately US$1.77 trillion valuation, and significantly contributed to Stack Capital’s...

Internet, Everywhere, Aug. 05, 2026 (GLOBE NEWSWIRE) — Shopify (NASDAQ, TSX: SHOP) announced today financial results for the quarter ended June 30, 2026. Shopify achieved 34% revenue growth (33% in constant currency) and 18% free cash flow margins. “This was a monster quarter: more than 30% growth in GMV AND revenue AND gross profit AND free cash flow,” said Harley Finkelstein, President of Shopify. “We power every kind of business, and with AI, we’re expanding what’s possible for all of them. No one else comes close.” “GMV growth accelerated on top of last year’s already strong Q2 with solid results across all merchant sizes, channels, and geographies. Alongside this momentum, we continue to drive operating leverage, which flowed through to 18% free cash flow margins. Broad-based, consistent, and compounding growth with financial...

MALTA, N.Y., Aug. 05, 2026 (GLOBE NEWSWIRE) — GLOBALFOUNDRIES Inc. (GF) (Nasdaq: GFS) today announced preliminary financial results for the second quarter ended June 30, 2026. Key Second Quarter Financial HighlightsRevenue of $1.786 billion Gross margin of 28.3% and Non-IFRS gross margin(1) of 29.9% Operating margin of 9.7% and Non-IFRS operating margin(1) of 16.7% Net income of $167 million and Non-IFRS net income(1) of $256 million Diluted earnings per share of $0.30 and Non-IFRS diluted earnings per share(1) of $0.46 Non-IFRS adjusted EBITDA(1) of $587 million Ending cash, cash equivalents and marketable securities of $3.3 billion Net cash provided by operating activities of $405 million and Non-IFRS adjusted free cash flow(1) of $(3) million“GF delivered strong results in the second quarter, with revenue and Non-IFRS...

AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone paymentsKey advances across pipeline, with further near-term clinical results anticipated for H2 2026 Phase 2 VacSYn trial of ACI-7104 in Parkinson’s disease supported by a $4 million grant from The Vijay and Marie Goradia Charitable Foundation Morphomer small molecule program targeting intracellular Tau progresses with Lilly Initiation of Alzheimer’s disease AD4 cohort in ABATE trial triggered $12 million milestone payment from TakedaCash resources of CHF 75.4 million as of June 30, 2026, provide funding into Q4 2027Lausanne, Switzerland, August 5, 2026 — AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted...

Solid revenue growth driven by Experiential and Retailer Services Reiterates full-year Revenues and Adjusted EBITDA guidance ranges Ended the quarter with $102.3M of cash ST. LOUIS, Aug. 05, 2026 (GLOBE NEWSWIRE) — Advantage Solutions Inc. (NASDAQ: ADV) (“Advantage,” “Advantage Solutions,” the “Company,” “we,” or “our”), a leading business solutions provider to consumer-packaged goods (CPG) brands and retailers, today reported financial results for the three and six months ended June 30, 2026. Revenues for the three months ended June 30, 2026 were $889.5 million compared with $873.7 million, and net loss was $62.7 million compared with a net loss of $30.4 million.    Q2’26 Financial Highlights•   Revenues increased 1.8% to $889.5 million and Adjusted EBITDA decreased 12.2% to $75.8 million•   Experiential...

Portfolio Receipts growth of 6% to $773 million; Royalty Receipts growth of 14% Net cash provided by operating activities of $728 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,400 million to $3,500 millionNEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts. “Royalty Pharma delivered strong second quarter results with Royalty Receipts growth of 14%,” said Pablo Legorreta, Royalty Pharma’s Chief Executive Officer and Chairman of the Board. “Our transaction pipeline remains exciting and we continued to bolster our development-stage pipeline in recent months, bringing total Capital Deployment to over $1 billion so far in 2026. Following our acquisition of...

MOUNT LAUREL, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) — J & J Snack Foods Corp. (Nasdaq: JJSF) today reported financial results for the third quarter ended June 27, 2026.    Third Quarter  Actuals $ v. LY * % v. LYNet Sales $426.0M ($28.3M) (6.2%)Gross Profit $151.0M $1.0M 0.6%Operating Income $46.3M ($14.3M) (23.6%)Net Earnings $35.3M ($8.9M) (20.1%)Earnings per Diluted Share $1.88 ($0.38) (16.8%)       Adjusted Operating Income $48.1M ($5.3M) (9.9%)Adjusted EBITDA $67.4M ($4.6M) (6.4%)Adjusted Earnings per Diluted Share $1.96 ($0.04) (2.0%)* Prior year reported results included a $9.1 million non-recurring net gain primarily related to the receipt of insurance proceeds. This press release contains non-GAAP financial measures. Please refer to the Non-GAAP Financial Measures section below...

Second Quarter 2026 Overview (all comparisons are made to the corresponding prior year second quarter unless otherwise specified):Net sales of $408.1 million, increased 23.6% Net income of $10.5 million; Adjusted net income of $21.8 million EBITDA of $35.6 million; Adjusted EBITDA of $42.6 million Diluted EPS of $0.45; Adjusted EPS of $0.94 Operating cash flow of $52.8 million year to date; Free cash flow of $37.3 million year to date Backlog of $601.1 million grew 57.9%CHATTANOOGA, Tenn., Aug. 05, 2026 (GLOBE NEWSWIRE) — Astec Industries, Inc. (Nasdaq: ASTE) announced today its financial results for the second quarter ended June 30, 2026. “We reported second quarter results with increased net sales, EBITDA and backlog. Materials Solutions orders continued to remain strong, while dealers reported healthy inventory levels...

102 MW of revenue-generating critical IT capacity online at Lake Mariner, with an additional 336 MW under construction and delivery expected within cost and schedule guidance Expands power-backed platform in Kentucky through ~$19 billion Anthropic lease at Justified and acquisition of the gigawatt-scale Muskie Data Campus Agrees to monetize Abernathy Joint Venture interest for ~$530 million and reaffirms target of contracting 250–500 MW of incremental critical IT capacity annually EASTON, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) — TeraWulf Inc. (Nasdaq: WULF) (“TeraWulf” or the “Company”), a vertically integrated owner, developer and operator of large-scale digital infrastructure, today announced its financial results for the second quarter ended June 30, 2026 and provided an update on its operations, development activities and strategic...

Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026 KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-579 (IRF5) Phase 1 healthy volunteer trial ongoing, with data expected in 4Q26 KT-485 (IRAK4) Phase 1 trial commenced in healthy volunteers and HS patients by partner Sanofi Well-capitalized with $1.5 billion in cash as of June 30, 2026, and runway into 2029 Company to hold video conference call and webcast today at 8:30 a.m. ET WATERTOWN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...